Development and Validation of the Visual Medical Scale to Evaluate Nail Psoriasis Severity (ViSENPsO®) - Report - MDSpire

Development and Validation of the Visual Medical Scale to Evaluate Nail Psoriasis Severity (ViSENPsO®)

  • By

  • Adilson DaCosta

  • Cláudio de Lélis Filgueiras de Souza

  • Renan Minotto

  • Selam Shah

  • Olga Moshkovich

  • James P. Stansbury

  • Siu-Long Yao

  • April 30, 2026

  • 0 min

Share

Clinical Report: Creation and Assessment of the Visual Medical Scale for Measuring Nail Psoriasis Severity (ViSENPsO®)

Overview

The ViSENPsO scale provides a standardized and user-friendly tool for assessing nail psoriasis severity, addressing limitations of existing tools like the Nail Psoriasis Severity Index (NAPSI). Its development involved qualitative and quantitative validation processes, aiming to enhance reliability and applicability in clinical trials.

Background

Nail psoriasis significantly affects quality of life in up to 90% of psoriasis patients, yet current assessment tools are often cumbersome and lack precision. The need for a simplified, validated tool is critical for improving the evaluation of nail psoriasis severity in clinical settings. The ViSENPsO scale aims to fill this gap by offering a more consistent and reliable assessment method.

Data Highlights

No numerical data was provided in the source material.

Key Findings

  • The ViSENPsO scale was developed to improve consistency and reliability in nail psoriasis assessment.
  • Existing tools like NAPSI have shown variable interobserver reliability, with ICCs of 0.78 for total scores and 0.65 for individual nail scores.
  • ViSENPsO was validated through concept elicitation and cognitive interviews with dermatologists and patients.
  • Further psychometric validation in larger populations is necessary to confirm the scale's applicability in clinical trials.
  • The scale incorporates illustrated outcomes to enhance clinician-reported evaluations.

Clinical Implications

The adoption of the ViSENPsO scale in clinical practice may lead to more accurate assessments of nail psoriasis severity, facilitating better treatment decisions. Its user-friendly design could improve clinician efficiency and patient outcomes in trials and routine care.

Conclusion

The ViSENPsO scale represents a significant advancement in the assessment of nail psoriasis severity, with the potential to standardize evaluations in clinical trials. Ongoing validation efforts will be crucial for its broader implementation.

References

  1. Clinical Rheumatology, 2023 -- Assessment of Microvascular Function in Juvenile Sjögren’s Disease: Initial Findings from Nailfold Videocapillaroscopy
  2. European Radiology, 2024 -- Advanced microvascular imaging techniques for assessing juvenile localized scleroderma activity: an initial investigation
  3. Clinical Rheumatology, 2024 -- Hematological Parameters in Psoriatic Enthesopathy: Correlation with Clinical and Ultrasound Assessments
  4. Knee Surgery, Sports Traumatology, Arthroscopy, 2021 -- Assessing Lower Limb Tendinopathy Using VISA Questionnaires: A Systematic Review Reveals Limited Evidence for Content and Structural Validity—Part I
  5. EMJ Reviews, 2025 -- Nail Psoriasis: A Narrative Review of Manifestations, Diagnosis and Management
  6. FDA Label Update, 2025 -- Adalimumab
  7. https://www.emjreviews.com/wp-content/uploads/2025/01/Nail-Psoriasis-A-Narrative-Review-of-Manifestations-Diagnosis-and-Management-.pdf
  8. label

Original Source(s)

Related Content